Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy

Hepatocellular Carcinoma Clinical Trial

Official title: Comparison of Outcomes in Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy: A Single Center Prospective Registry Study

Status Enrolling by invitation

Clinical Trial Summary

This will be a study to examine the outcomes of open, laparoscopic, and robotic Living Donor Liver Transplantation (LDLT) procedures. The analysis will encompass 3,448 cases (1,724 donor-recipient pairs) from January 2011 to March 2023, documenting the transition between these surgical techniques, with a noted crossover in 2018.

Clinical Trial Description

Background: Liver transplantation is a primary treatment for end-stage liver disease, enhancing survival rates and life quality. Living donor liver transplantation (LDLT) has gained prominence due to the scarcity of deceased donor organs. Historically, the open technique dominated living donor hepatectomies. However, advances in minimally invasive surgery (MIS) led to laparoscopic and later robotic procedures. With the introduction of robotic surgery, MIS for complex surgeries improved, offering better precision and ergonomics. Objective: To compare the short and long-term outcomes of open, laparoscopic, and robotic LDLT, focusing on both donors and recipients. Methods: Study Design: Retrospective analysis of data from a prospective liver transplant registry, examining three LDLT techniques. Setting: King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Participants: All consecutive living donor and recipient pairs undergoing LDLT between January 2011 and March 2023. Exclusions include dual or domino LDLT. Surgical Techniques: Open, laparoscopic, and robotic techniques used for donor hepatectomies. Variables: Primary focus on morbidity, conversion rates, and in-hospital mortality for both donors and recipients. Secondary variables will include major complications, graft, and recipient survival rates. Data Sources and Measurement: Data sourced from a secured, encrypted transplant database, detailing patient data, operation characteristics, and post-op outcomes. Complication severity will be captured using the Clavien-Dindo classification and Comprehensive Complication Index™. Study Size: Determined by the total number of procedures during the study duration, deemed sufficient for comparison. Quantitative Variables: Demographics, comorbidities, operational details, post-op and long-term outcomes. Statistical Methods: Various statistical tests will be employed for comparison, including the Student t, Mann-Whitney U, one-way ANOVA, Fischer and Chi square. Survival will be evaluated using the Kaplan-Meier method. Multivariable binary logistic regression will be employed. All statistical analyses will be conducted using R. Ethics Approval: Obtained (ID: RAC 2121012) and in accordance with the 1964 Helsinki declaration. ;

Related Conditions & MeSH terms

• Acute Liver Failure
• Acute-On-Chronic Liver Failure
• End Stage Liver Disease
• Hepatic Insufficiency
• Hepatocellular Carcinoma
• Liver Diseases
• Liver Failure
• Liver Failure, Acute

• NCT number: NCT06062706
• Study type: Observational [Patient Registry]
• Source: King Faisal Specialist Hospital & Research Center
• Status: Enrolling by invitation
• Start date: August 6, 2023
• Completion date: October 30, 2023